收费全文 | 28876篇 |
免费 | 1793篇 |
国内免费 | 220篇 |
耳鼻咽喉 | 346篇 |
儿科学 | 770篇 |
妇产科学 | 973篇 |
基础医学 | 3220篇 |
口腔科学 | 791篇 |
临床医学 | 2425篇 |
内科学 | 6106篇 |
皮肤病学 | 558篇 |
神经病学 | 1361篇 |
特种医学 | 1036篇 |
外国民族医学 | 12篇 |
外科学 | 4818篇 |
综合类 | 625篇 |
现状与发展 | 2篇 |
一般理论 | 18篇 |
预防医学 | 2328篇 |
眼科学 | 887篇 |
药学 | 2642篇 |
中国医学 | 238篇 |
肿瘤学 | 1733篇 |
2023年 | 399篇 |
2022年 | 1074篇 |
2021年 | 1540篇 |
2020年 | 894篇 |
2019年 | 1139篇 |
2018年 | 1451篇 |
2017年 | 921篇 |
2016年 | 932篇 |
2015年 | 933篇 |
2014年 | 1332篇 |
2013年 | 1574篇 |
2012年 | 2248篇 |
2011年 | 2375篇 |
2010年 | 1387篇 |
2009年 | 1059篇 |
2008年 | 1495篇 |
2007年 | 1518篇 |
2006年 | 1331篇 |
2005年 | 1263篇 |
2004年 | 1102篇 |
2003年 | 985篇 |
2002年 | 886篇 |
2001年 | 290篇 |
2000年 | 249篇 |
1999年 | 237篇 |
1998年 | 144篇 |
1997年 | 121篇 |
1996年 | 117篇 |
1995年 | 113篇 |
1994年 | 105篇 |
1993年 | 81篇 |
1992年 | 118篇 |
1991年 | 121篇 |
1990年 | 130篇 |
1989年 | 106篇 |
1988年 | 112篇 |
1987年 | 108篇 |
1986年 | 99篇 |
1985年 | 84篇 |
1984年 | 78篇 |
1983年 | 58篇 |
1982年 | 56篇 |
1981年 | 35篇 |
1980年 | 42篇 |
1979年 | 40篇 |
1978年 | 27篇 |
1977年 | 41篇 |
1976年 | 40篇 |
1974年 | 28篇 |
1973年 | 36篇 |
Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献